Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
144 Colorectal Cancer Trials near Boston, MA
Power is an online platform that helps thousands of Colorectal Cancer patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerDuloxetine for Colorectal Cancer
Boston, MassachusettsThis phase II/III trial studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy.
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Age:25+
Sex:All
220 Participants Needed
Nivolumab-relatlimab Combo for Colorectal Cancer
Boston, MassachusettsThis trial is testing a combination of two drugs, relatlimab and nivolumab, for patients with a certain type of colorectal cancer who haven't responded to other treatments. The drugs help the immune system attack the cancer.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
700 Participants Needed
MRTX849 + Cetuximab for Colorectal Cancer
Boston, MassachusettsThis trial is testing a new treatment for patients with colorectal cancer. The treatment combines two drugs that work together to block cancer growth and prevent its spread. One of the drugs has shown promise in treating other types of cancer as well.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
461 Participants Needed
Vitamin D3 + Chemotherapy + Bevacizumab for Colorectal Cancer
Brighton, MassachusettsThis trial is testing if vitamin D3 along with regular cancer drugs and another drug that helps the immune system can better treat colorectal cancer that has spread. Vitamin D3 may help the body use essential minerals, making the cancer drugs more effective. Vitamin D3 has been shown to slow down cancer cell growth and help them mature, and it has been effective in reducing intestinal tumors in animal studies.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
455 Participants Needed
Eflornithine + Sulindac for Colorectal Cancer Prevention
Jamaica Plain, MassachusettsThe investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
354 Participants Needed
Colonoscopy for Colorectal Cancer
Boston, MassachusettsColorectal cancer (CRC) is a major burden in western countries. The disease develops from precursor lesions during a long time-interval. Colonoscopy can detect and remove CRC precursor lesions and may thus be effective for CRC prevention. Many national and international health organisations demand evidence from randomised trials to reduce incidence or mortality of the target disease before advocating population-wide cancer screening. However, while colonoscopy screening for the prevention of colorectal cancer is established in the United States and several European countries, no randomised trials exist to quantify the possible benefit of colonoscopy screening. NordICC is a randomised trial investigating the effect of colonoscopy on CRC incidence and mortality.
NordICC is a multicentre, randomised trial in Nordic countries, the Netherlands and Poland. A minimum of 66 000 individuals, age 55-64 years, are drawn randomly from the population registries in the participating countries. 22 000 are invited for once-only colonoscopy (2:1 randomisation). Expected work-load with 50% compliance will be 11,000 colonoscopies. At the screening examination, all detected lesions are biopsied and removed whenever possible. The remaining 44 000 individuals (control group) are not offered any screening examination (care as usual).The primary study aims are CRC incidence and CRC mortality after 15 years of follow-up, with an interim analysis after 10 years of follow-up. In an intention-to-treat approach, a risk reduction of CRC mortality of 25% in the colonoscopy screening group compared to the control group is expected after 10 years follow-up, estimating 50% compliance in the screening group.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:55 - 64
Sex:All
95000 Participants Needed
Fruquintinib for Colorectal Cancer
Boston, MassachusettsHigh blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib for refractory mCRC. Other aims are to learn how safe fruquintinib is and how well it is tolerated by participants.
Participants will receive fruquintinib in 4-week treatment cycles until their condition worsens, they do no longer tolerate the treatment or stop the treatment for other reasons. After the last treatment, participants will be checked upon every 3 months until study completion.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Hypertension, Cardiovascular Disease, Others
Must Not Be Taking:Anticoagulants, TKIs, CYP3A4 Inducers
78 Participants Needed
Coffee for Colorectal Cancer
Boston, MassachusettsThis is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery, chemotherapy and radiotherapy) for stage I-III colorectal cancer.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, HIV, Hepatitis, Others
Must Not Be Taking:Chemotherapy, Immunotherapy, Others
80 Participants Needed
Cancer Vaccines for Lynch Syndrome
Boston, MassachusettsThis trial tests a vaccine and an immune booster to prevent cancer in people with Lynch syndrome. The vaccine teaches the body to fight cancer, and the booster makes this process stronger. Vaccines have shown robust potential for preventing Lynch syndrome cancers.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, HIV, Hepatitis, Others
Must Not Be Taking:Corticosteroids, Immunosuppressants, Others
186 Participants Needed
JDQ443 Combinations for Advanced Cancer
Boston, MassachusettsThis trial tests JDQ443, a new drug, combined with other treatments for patients with advanced cancers having the KRAS G12C mutation. The drug aims to stop cancer growth by targeting a specific genetic fault.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 100
Sex:All
74 Participants Needed
Epacadostat + Chemoradiation for Rectal Cancer
Boston, MassachusettsThe purpose of this research study is to evaluate epacadostat when given with routine radiation therapy and chemotherapy (capecitabine and oxaliplatin) to treat rectal cancer before routine surgery is performed to remove the tumor.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Other Cancer, Metastatic Disease, Autoimmune, Others
Must Not Be Taking:Warfarin, MAOIs, Others
49 Participants Needed
FOG-001 for Cancer
Boston, MassachusettsThis trial is testing FOG-001, a new medicine, to see if it is safe and effective for patients with advanced or spreading solid tumors. FOG-001 works by blocking certain proteins to stop cancer cells from growing.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Bone Metastasis, Osteoporosis, Inflammatory Bowel Disease, Others
480 Participants Needed
SNDX-5613 for Colorectal Cancer
Boston, MassachusettsThis study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of revumenib in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
42 Participants Needed
Botensilimab + Balstilimab for Colorectal Cancer
Boston, MassachusettsThis trial tests botensilimab alone or with balstilimab in adults with advanced colorectal cancer who didn't respond to previous chemotherapy. The new drugs aim to enhance the immune system's ability to fight cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
234 Participants Needed
MCLA-158 for Solid Cancers
Boston, MassachusettsThis trial is testing a new drug called MCLA-158 to see if it can help treat certain cancers by blocking a protein that helps cancer cells grow. It focuses on patients with cancers that rely on this protein, like colorectal and head and neck cancers.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Uncontrolled Hypertension, Others
Must Not Be Taking:Immunosuppressants
523 Participants Needed
Nivolumab + Ipilimumab + Radiation for Colorectal and Pancreatic Cancer
Boston, MassachusettsThis research study is studying a combination of drugs with radiation therapy as a possible treatment for Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, or MSI High Colorectal Cancer.
The interventions involved in this study are:
* Nivolumab
* Ipilimumab
* Radiation Therapy
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Active Infection, HIV, Others
Must Not Be Taking:Immunosuppressants, Corticosteroids
80 Participants Needed
LUM Imaging System for Gastrointestinal Cancer
Boston, MassachusettsThe overall goal of this feasibility study is to assess the initial safety and efficacy of LUM015 in ex vivo far-red imaging of colorectal, pancreatic, and esophageal cancers (adenocarcinoma) using the LUM Imaging System.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Hypertension, Allergies To PEG, Others
Must Not Be Taking:Investigational Drugs, Antiretrovirals
66 Participants Needed
Adagrasib + Cetuximab + Cemiplimab for Colorectal Cancer
Boston, MassachusettsTo learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Autoimmune Disease, Brain Metastases, Others
Must Not Be Taking:Immunosuppressants, Corticosteroids, Proton Pump Inhibitors, Others
31 Participants Needed
Novel Interventions for Colorectal Cancer
Boston, MassachusettsThe main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
120 Participants Needed
DKN-01 for Colorectal Cancer
Boston, MassachusettsThis trial tests a new drug, DKN-01, combined with standard chemotherapy and bevacizumab for advanced colorectal cancer patients who didn't respond to earlier treatment. The treatment works by attacking cancer cells, blocking growth signals, and cutting off their blood supply.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
188 Participants Needed
LYL845 for Solid Cancers
Boston, MassachusettsThis is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 75
Sex:All
108 Participants Needed
Aspirin for Colorectal Cancer
Boston, MassachusettsThis research study is studying a drug intervention as a possible chemoprevention strategy for colorectal cancer.
The name of the study intervention involved in this study is:
* Low Dose Aspirin
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1
Age:18+
Sex:All
161 Participants Needed
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody for Advanced Cancer
Boston, MassachusettsThis trial is testing two new drugs that help the immune system fight cancer. It targets adults with advanced cancers that haven't responded to other treatments. The drugs work by blocking proteins that usually prevent the immune system from attacking cancer cells.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
499 Participants Needed
SGN-EGFRd2 for Advanced Cancer
Boston, MassachusettsThis study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.
Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic).
This study will have three parts. Parts A and B of the study will find out how much PF-08046052/SGN-EGFRd2 should be given to participants. Part C will use the dose found in parts A and B to find out how safe PF-08046052/SGN-EGFRd2 is and if it works to treat solid tumor cancers.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Active CNS Metastases, Recent Thromboembolism, Others
Must Not Be Taking:Aminobisphosphonates
275 Participants Needed
RMC-6291 for Solid Cancers
Boston, MassachusettsThis trial tests a new drug, RMC-6291, in adults with advanced cancers that have a specific mutation. The drug aims to block a faulty protein in these cancer cells to stop their growth.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
222 Participants Needed
XL092 + Immuno-Oncology Agents for Solid Tumors
Boston, MassachusettsThis trial is testing a new drug called XL092 alone and with other cancer drugs in patients with advanced solid tumors. The goal is to see if these treatments can safely stop or slow tumor growth and help the immune system fight cancer more effectively.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Uncontrolled Illness, Pregnancy, Others
Must Not Be Taking:Anticoagulants, Complementary Medicines
1274 Participants Needed
GDC-6036 for KRAS G12C-Mutated Cancers
Boston, MassachusettsThis trial is testing a new drug called GDC-6036 in patients with advanced or metastatic solid tumors that have a KRAS G12C mutation. The drug works by blocking a faulty part of the cancer cells' genetic code to stop their growth.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Malabsorption, Cardiovascular Dysfunction, Others
498 Participants Needed
PF-07985045 for Cancer
Boston, MassachusettsThe purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
This study also aims to find the best amount of study medication.
This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that:
* are advanced (cancer that doesn't disappear or stay away with treatment) and
* have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to grow in very high numbers).
This includes (but limited to) the following cancer types:
* Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body.
* Colorectal Cancer (CRC): This is a disease where cells in the colon (a part of large intestine) or rectum grow out of control.
* Pancreatic ductal adenocarcinoma (PDAC): This is a cancer that starts in the ducts of the pancreas but can spread quickly to other parts of the body. Pancreas is a long, flat gland that lies in the abdomen behind the stomach. Pancreas creates enzymes that help with digestion. It also makes hormones that can help control your blood sugar levels.
All participants in this study will take the study medication (PF-07985045) as pill by mouth once a day. This will be repeated for 21-day or 28-day cycles.
Depending on which part of the study participants are enrolled into they will receive the study medication (PF-07985045 alone or in combination with other anti-cancer medications). These anti-cancer medications will be given in the study clinic by intravenous (IV) that is directly injected into the veins at different times (depending on the treatment) during the 21-day or 28-day cycle.
Participants can continue to take the study medication (PF-07985045) and the combination anti-cancer therapy until their cancer is no longer responding.
The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective.
Participants will be in this study for up to 4 years. During this time, the participants will come into the clinic for 1 to 4 times in each 21-day or 28-day cycle. After the participants have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
190 Participants Needed
Decision Support Tool for Colorectal Cancer
Boston, MassachusettsThe research question we pose is, Does a colorectal cancer (CRC) screening decision support tool offered in advance of primary care visits increase CRC screening completion rates? Our work aims to answer this question by evaluating the effectiveness of an MGB decision support tool to 1) promote informed decisions about CRC screening for average risk patients ages 45-75, 2) deploy a decision support tool as part of a primary care bundle questionnaire, and 3) support patients in completing their preferred method of CRC screening.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:45 - 75
Sex:All
80000 Participants Needed
Exercise for Colorectal Cancer
Boston, MassachusettsThis research study is a randomized controlled trial that will observe changes in microbiome activity, changes in chemotherapy toxicity, and any changes in treatment outcomes between two groups of participants undergoing chemotherapy with either early-stage or metastatic colorectal cancer.
The names of the study groups involved in this study are:
* Exercise
* Waitlist Control
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 50
Sex:All
Key Eligibility Criteria
Disqualifiers:Unstable Comorbidities, Excessive Exercise, Others
84 Participants Needed
Page 1 of 5+
Learn More About Power
My name is Bask, and I helped to start the company here. We started Power when my Dad was diagnosed with multiple myeloma, and I needed a better way to understand how he could access the most promising immunotherapy for his illness.
Bask GillCEO at Power
Frequently Asked Questions
How much do Colorectal Cancer clinical trials in Boston, MA pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Colorectal Cancer clinical trials in Boston, MA work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Colorectal Cancer trials in Boston, MA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Boston, MA for Colorectal Cancer is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Boston, MA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Colorectal Cancer medical study in Boston, MA ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Colorectal Cancer clinical trials in Boston, MA ?
Most recently, we added ELS System for Colon Polyps, Novel Interventions for Colorectal Cancer and ALTA3263 for Cancer to the Power online platform.